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Background: The DESolve Bioresorbable Coronary Scaffold is a novel drug-eluting
device combining a PLLA-based scaffold coated with a bioresorbable polylactide-based
polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor, has
demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using
Elixir’s metallic coronary stents. The drug dose is 3 mcg per mm of scaffold length. We
aimed to present the IVUS results of the first-in-man evaluation of this novel scaffold.
Methods: The DESolve FIM trial enrolled 15 patients, treated with a single 3.0x14 mm
DESolve at 3 centers. IVUS was performed at the end of the procedure and repeated at
six-month invasive follow-up. Complete and adequate IVUS images at baseline and
follow-up were obtained for 11 cases. Serial changes in vessel volume, scaffold area and
the degree of NIH formation were assessed. All analyses were performed by an
independent core laboratory.
Results: From baseline to 6 months, IVUS showed a small increase in scaffold mean area
(from 5.35  0.78 mm2 to 5.61  0.81 mm2). Additionally, there was no significant
change in vessel volume (from 148.0  37.0 mm3 to 150.03  35.38 mm3) or area,
demonstrating the absence of constrictive or expansive remodelling. There was very low
neointimal volume (5.6  2.8 mm3) and % scaffold obstruction (7.18  3.37%). and no
cases of incomplete strut apposition.
Conclusions: The DESolve scaffold demonstrated a unique property of expansion and no
chronic recoil from baseline to follow-up. Results at 6 months showed effective
neointimal suppression and no late strut malapposition thus suggesting a very efficacious
and novel bioresorbable scaffold.
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Background: Positive vessel remodeling, caused by an increase in peri-stent plaque
volume during follow-up, has frequently been demonstrated in clinical studies of
paclitaxel-eluting stents (PES). Histopathologic studies have also shown an association of
positive remodeling with vessel inflammation, possibly related to the occurrence of very
late stent thrombosis. This study aimed to investigate the determinants of vessel
remodeling in patients treated with PES as assessed by IVUS.
Methods: Serial (post-procedure and 8-9 months follow-up) volumetric IVUS data were
analyzed in 227 de novo coronary lesions electively treated with PES. Volume index (VI)
was defined as volume/length (mm3/mm). Peri-stent plaque VI was standardized by stent
VI (%PVI). Vessel remodeling during follow-up was assessed as a change of peri-stent
plaque VI per stent VI. Morphologic properties with a p-value0.10 on univariate
analysis were inserted into multivariate models.
Results: Overall, the change of vessel VI during follow-up was 5.08.1% (range:
-21.7% to 	36.1%), resulted from a significant increase of %PVI (95.929.9% to
103.928.9%, p0.0001). Among IVUS parameters at post-procedure, vessel VI and
%PVI had significant inverse correlations with positive vessel remodeling (p0.002,
p0.0002, respectively). In multivariate analysis, less %PVI at post-procedure was
independently associated with positive vessel remodeling during follow-up (p0.02).
Conclusions: This pooled IVUS analysis identified thinner peri-stent plaque surrounding
PES at baseline as a predictor of larger positive vessel remodeling during follow-up. This
may reflect the differential mechanical compliance and/or increased drug infiltration into
the deep vessel wall structure in the setting of less underlying plaque behind the stent.
Variable
Positive Vessel Remodeling
Univariate Analysis Multivariate Analysis
Regression
Coefficient
() 95% CI p
Regression
Coefficient
() 95% CI p
IVUS Parameter at Post Procedure
Stent
Length
(mm)
0.051 0.003
–0.002
0.446
Stent VI
(mm3/mm)
0.087 0.013
–0.003
0.191
Vessel VI
(mm3/mm)
0.209 0.010
–0.002
0.002 0.083 0.013
–0.018
0.751
%PVI (%) 0.242 0.168
–0.052
0.0002 0.297 0.248
–0.021
0.020
Minimum
Lumen
Area(mm2)
0.122 0.017
–0.001
0.067 0.233 0.049
–0.018
0.358
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Background: It is unknown whether IVUS utilization during percutaneous coronary
intervention (PCI) may modify the stent length effect on clinical outcomes. We sought to
find differential prognostic impact of intravascular ultrasound (IVUS) utilization accord-
ing to the implanted stent length.
Methods: Between April 2008, and June 2010, we enrolled 3244 consecutive patients
underwent single or overlapping stent implantation at 46 academic or community
hospitals in Korea. The primary endpoint was a composite of death, myocardial infarction,
or target vessel revascularization (MACE). Study population was divided by the tertiles of
implanted stent length and IVUS utilization.
Results: After adjustment for significant covariates, implanted stent length was not
significantly associated with the risk of MACE in IVUS group (hazard ratio [HR] 1.08,
95% confidence interval [CI] 0.97-1.20, p0.16), whereas implanted stent length was
significantly associated with the risk of MACE in no IVUS group (HR 1.13, 95% CI
1.01-1.28, p0.042). In addition, in patients with implanted stent length of 22mm
(N998), the risk of MACE was not significantly different between IVUS group and no
IVUS group (HR 1.06, 95% CI 0.50-2.28, p0.88). By contrast, in patients with longer
implanted stent length, the risk of MACE was significantly lower in IVUS group than in
no IVUS group (HR 0.47, 95% CI 0.24-0.92, p0.027 for 23-32mm [N1109], HR 0.57,
95% CI 0.33-0.98, p0.042 for 33mm [N1137]).
Conclusions: IVUS utilization may attenuate the detrimental effect of the increase of
implanted stent length, supporting the favor of IVUS utilization, particularly during PCI
with the long stent implantation.
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Background: Assessment of the side branch (SB) ostium by angiography and 2D optical
coherence tomography (OCT) is challenging. This is the first presentation of ostial SB
assessment by centerline guided 3D OCT.
Methods: The study was a substudy to the SORT-OUT V OCT study comparing a
sirolimus eluting durable polymer stent (Cypher Select	, Cordis, US) and a biolimus
eluting biodegradable polymer stent (Nobori, Terumo, JP). The SB ostium was evaluated
in all SBs visible on both baseline and 12-month follow-up OCT. Each SB ostium was
reconstructed in 3D by the main vessel OCT acquisition using QAngioOCT prototype
(Medis medical imaging systems, NL). The minimal luminal area (MLA) was assessed up
to one millimeter into the SB. The measurement plane (the cut plane), was reconstructed
perpendicular to the SB centerline. In case of neointimal bridging over the SB ostium, the
areas of the individual ostia of the same SB were summed.
Results: Matched baseline and FU OCT was available in 96 patients. At baseline 208
SBs were detected and of these were 107(51%) in-stent SBs. SBs were not analyzable due
to wire shadow in 49 (23%) SBs and due to impaired image quality in 26 (12.5%) of SBs.
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